Imugene (AU:IMU)
ASX:IMU
IMU Stock Chart & Stats
AU$0.33
>-AU$0.01(-2.22%)
At close: 4:00 PM EST
AU$0.33
>-AU$0.01(-2.22%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$1.02
Previous CloseN/A
Volume11.90M
Average Volume (3M)877.83K
Market Cap
AU$51.77M
Enterprise ValueAU$42.65M
Total Cash (Recent Filing)AU$14.14M
Total Debt (Recent Filing)AU$5.02M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding357,010,350
10 Day Avg. Volume850,615
30 Day Avg. Volume877,834
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.18
Revenue Forecast (FY)AU$5.00M
Bulls Say, Bears Say
Bulls Say
Diversified Immuno-oncology PipelineImugene's portfolio of multiple clinical-stage immuno-oncology candidates (CF33 series, PD1-Vaxx, HER-Vaxx) spreads development risk across mechanisms and indications. This durable diversification increases the chance of a successful asset, permits parallel partnering strategies, and supports longer-term development optionality over months.
Conservative Capital StructureA low debt-to-equity ratio and moderate equity financing indicate limited leverage and reduced fixed interest burden. This conservative balance sheet provides financial flexibility to fund clinical programs, lowers insolvency risk, and gives management time to execute partnering or financing strategies without urgent refinancing pressure.
Clear Monetization Pathways Via PartnershipsThe company's explicit reliance on capital raises, grants and potential collaborations/licensing is a durable business model feature for clinical-stage biotech. Strategic partnerships or licensing can provide non-dilutive or co-funded development, external expertise and milestone-based funding, reducing sole dependence on internal cash sources.
Bears Say
Severe Revenue DeclineA reported revenue decline of -338.95% represents a dramatic top-line collapse, indicating little to no commercial receipt and heavy reliance on external financing. Over the medium term this erodes operational resilience, limits reinvestment capacity, and heightens the need for fundraising or partner deals to sustain clinical programs.
Deep Negative Profitability And ROESustained negative profitability and a ROE of -153.27% show the company is destroying shareholder equity rather than generating returns. This structural lack of profitability reduces retained capital for R&D, complicates access to non-dilutive funding, and undermines long-term investor confidence in operational effectiveness.
Weak Operating Cash GenerationNegative operating cash flows mean core operations consume cash, forcing dependence on capital markets, grants or partnerships. Persistent operating outflows increase dilution and execution risk for ongoing trials, making it harder to sustain multi-stage clinical programs without frequent external financing.
Imugene News
IMU FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest share price was AU$0.13 and its highest was AU$1.02 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is AU$51.77M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Aug 28, 2026 which is in 145 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -AU$0.13 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.21.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imugene have?
Imugene has 357,010,350 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -AU$0.13 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in AU:IMU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IMU Sentiment 76%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.71%
12-Months-Change
Fundamentals
Return on Equity
-134.65%
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---